Using Nalbuphine with Bupivacaine for Pain Relief in Thyroid Surgery
The Analgesic Efficacy of Perineural Nalbuphine as an Adjuvant to Bupivacaine in Ultrasound Guided Superficial Cervical Plexus Nerve Block for Thyroid Surgeries. A Double Blinded Randomized Controlled Trial.
This study is testing whether adding nalbuphine to bupivacaine can help people feel less pain after thyroid surgery and reduce the need for stronger pain medications.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Enrollment | 54 (estimated) |
| Ages | 18 Years to 60 Years |
| Sex | All |
| Sponsor | Cairo University Academic / other |
| Locations | 1 site (Giza, الجيزة) |
| Trial ID | NCT06633068 on ClinicalTrials.gov |
What this trial studies
This study evaluates the effectiveness of adding nalbuphine as an adjuvant to bupivacaine in providing pain relief during and after thyroid surgeries. It focuses on the analgesic effects in the first 24 hours post-operation, measuring factors such as the need for rescue analgesia and the incidence of complications like nausea and respiratory depression. The approach involves a double-blinded randomized controlled trial design to ensure unbiased results. The goal is to improve postoperative pain management while minimizing opioid-related side effects.
Who should consider this trial
Good fit: Ideal candidates are patients aged 18 to 60 years undergoing elective thyroid surgery with ASA I and II classifications.
Not a fit: Patients with hypersensitivity to nalbuphine or bupivacaine, or those with significant comorbidities such as hepatic, cardiac, or renal diseases may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could significantly enhance pain management for patients undergoing thyroid surgery while reducing reliance on opioids.
How similar studies have performed: Other studies have shown promising results with similar approaches in pain management, suggesting potential for success in this trial.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients aged between 18 to 60 years old of both sexes undergoing elective thyroid surgery. * ASA I and II. Exclusion Criteria: * Patient refusal. * Hypersensitivity or contraindication to nalbuphine or bupivacaine. * Pregnancy or lactating mothers. * Hepatic, cardiac or renal diseases. * Bleeding disorders. * Severe neurological or psychological disorders. * Goitres with retrosternal extension. * Any anatomical disruption in the neck (ex: metastatic lymph nodes).
Where this trial is running
Giza, الجيزة
- Kasr Alainy Teaching Hospitals — Giza, الجيزة, Egypt (Recruiting)
Study contacts
- Study coordinator: Sara M Badie, Master degree
- Email: sarabadie1993@gmail.com
- Phone: 0109588821
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.